Jeffrey B Matthews
Overview
Explore the profile of Jeffrey B Matthews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
2206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McKenzie N, Dorsey C, Guerrero S, Donington J, Alverdy J, Nordgren R, et al.
Surgery
. 2025 Jan;
180():109023.
PMID: 39837048
Background: Black, Indigenous, People of Color (BIPOC) in medicine and women faculty have lower 10-year promotion rates than their White and male peers, despite controlling for productivity metrics. Promotion standards...
2.
Rugo H, Campbell M, Yau C, Jo Chien A, Wallace A, Isaacs C, et al.
Breast Cancer Res Treat
. 2024 Dec;
209(3):487-492.
PMID: 39625569
Purpose: We investigated the small-molecule receptor tyrosine kinase-inhibitor of colony-stimulating factor-1 receptor pexidartinib in the stage II/III breast cancer in the I-SPY2 platform trial. Methods: I-SPY2 is an adaptive platform...
3.
Shatsky R, Trivedi M, Yau C, Nanda R, Rugo H, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3737-3747.
PMID: 39277672
Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan...
4.
Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3728-3736.
PMID: 39277671
Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer...
5.
Vigneswaran J, Ogunnowo S, Millis J, Roggin K, Posner M, Matthews J, et al.
Am J Surg
. 2024 Jul;
236:115834.
PMID: 38991911
Background: Across surgery, marginalized individuals experience worse postoperative outcomes. These disparities stem from the interplay between multiple factors. Methods: We introduced a novel framework to assess the role of barriers...
6.
Stain S, Ellison E, Farmer D, Flynn T, Freischlag J, Matthews J, et al.
Ann Surg
. 2024 May;
280(4):535-546.
PMID: 38814074
Objective: An expert panel made recommendations to optimize surgical education and training based on the effects of contemporary challenges. Background: The inaugural Blue Ribbon Committee (BRC I) proposed sweeping recommendations...
7.
Pathak K, Marwaha J, Chen H, Krumholz H, Matthews J
JAMA Surg
. 2023 Dec;
159(2):228-229.
PMID: 38117492
No abstract available.
8.
Albain K, Yau C, Petricoin E, Wolf D, Lang J, Jo Chien A, et al.
Clin Cancer Res
. 2023 Dec;
30(4):729-740.
PMID: 38109213
Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients...
9.
Gallagher R, Wulfkuhle J, Wolf D, Brown-Swigart L, Yau C, OGrady N, et al.
Cell Rep Med
. 2023 Dec;
4(12):101312.
PMID: 38086377
Molecular subtyping of breast cancer is based mostly on HR/HER2 and gene expression-based immune, DNA repair deficiency, and luminal signatures. We extend this description via functional protein pathway activation mapping...
10.
Zhang L, Symalla T, Roggin K, Matthews J, Hussain M
Ann Surg Open
. 2023 Aug;
2(1):e042.
PMID: 37638236
Objective: To create a COVID-19 based educational curriculum for surgical residents. Background Data: The COVID-19 pandemic has resulted in disruptions to operative volume and clinical education for surgery residents. This...